麻豆传媒

 Benefits may be most pronounced for Black women and patients diagnosed with later-stage disease

• Song Yao, PhD, led research effort to be highlighted during ASCO 2021 meeting
• New analysis based on Kaiser Permanente Northern California’s Pathways Study
• Higher vitamin D levels at diagnosis linked to better breast cancer outcomes

News — BUFFALO, N.Y. — The joint Roswell Park Comprehensive Cancer Center/Kaiser Permanente Northern California team behind a new study to be highlighted at the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting has found that sufficient vitamin D levels at the time of diagnosis are associated with improved outcomes among people with breast cancer.

The new research, presented by first author , is based on Kaiser Permanente Northern California’s Pathways Study — a large prospective study in breast cancer patients that has been underway since 2006 under the direction of , who is Senior Author on the new study. Dr. Yao highlighted the team’s findings in a poster discussion session today. The presentation is (abstract 10510).

“Consistent with results from randomized trials and meta-analyses, our findings from this large, observational cohort of breast cancer survivors with long follow-up provide the strongest evidence to date for maintaining sufficient vitamin D levels in breast cancer patients, particularly among Black women and patients with more advanced stage disease,” notes Dr. Yao, a molecular epidemiologist and Professor of Oncology with the Department of Cancer Prevention and Control at Roswell Park.

“These findings highlight not just the role of vitamin D in breast cancer prognosis, but also the contribution of and need for prospective studies in cancer survivors to complement clinical trials," says study Senior Author , Director of Scientific Policy at the Kaiser Permanente Northern California Division of Research.

The research team measured 25-hydroxyvitamin D (25OHD) levels from 3,995 women with breast cancer who were enrolled in the Pathways Study, using blood serum samples collected at the time of diagnosis. They examined potential determinants of 25OHD levels, including polygenic score. Vitamin D supplement intake, BMI, and race/ethnicity were the most influential factors on serum 25OHD levels, while genetic variants had only a limited impact, notes Dr. Yao.

The study categorized vitamin D levels based on clinical cutoffs: deficient (< 20 ng/ml), insufficient (20 to < 30 ng/ml), or sufficient (≥30 ng/ml). Dr. Yao and colleagues then evaluated these levels in relation to overall survival (OS), breast cancer-specific survival (BCSS), recurrence-free survival (RFS), and invasive disease-free survival (IDFS) after a median follow-up time of 9.6 years. The researchers built Cox proportional hazards models adjusting for non-clinical, clinical and treatment factors that were further stratified by stage, estrogen receptor (ER) status and body mass index (BMI).

“Having clinically sufficient vitamin D levels at the time of breast cancer diagnosis is associated with better outcomes,” Dr. Yao notes. “While these results are consistent with our earlier analysis based on a subset of the study population, it’s significant that we saw the same trends in this much larger, longer-term data set — suggesting an ongoing benefit for patients who maintain sufficient levels through and beyond breast cancer treatment.”

The team also observed that associations were similar by ER status, and found that the association between vitamin D levels and breast cancer outcomes appeared to be stronger among study participants diagnosed at more advanced stages or with lower body mass index. Black women had the lowest vitamin D levels, which might contribute to their generally poorer outcomes after breast cancer diagnosis.

“In the context of supportive data from recent randomized trials and meta-analyses, our findings support the use of daily vitamin D supplementation to maintain sufficient vitamin D levels after breast cancer diagnosis, particularly among Black women and patients diagnosed with later-stage disease,” says senior author , Co-Principal Investigator of the Pathways Study and Senior Vice President of Population Sciences and Chair of Cancer Prevention and Control at Roswell Park.

###

This news release is also available on the Roswell Park website:

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer’s grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at or contact us at 1-800-ROSWELL (1-800-767-9355) or [email protected].